Zacks Investment Research on MSN6h
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock DownEditas Medicine EDIT reported a loss of 55 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus ...
Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...
The possibility of ending the HIV epidemic in Europe is more tangible than ever, but the actions we take now will determine ...
Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...
As the U.S. stock market experiences a surge following a temporary reprieve from tariffs on automakers, investors are keenly observing the fluctuations in major indices like the Dow Jones Industrial ...
The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and ...
A weekly programme that illuminates the mysteries and challenges the controversies behind the science that's changing our world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback